AIP
IMVT icon

Arrowpoint Investment Partners’s Immunovant IMVT Stock Holding History

Arrowpoint Investment Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
+9,043
New +$276K 0.08% 84
2026
Q1 		– Sell
-13,714
Closed -$349K – 115
2025
Q4 		$349K Buy
+13,714
New +$306K 0.05% 82

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arrowpoint Investment Partners's IMVT Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Immunovant (IMVT) in Q2 2026: 9,043 shares worth $348K. The stake represents 0.08% of the portfolio and ranks #84 among its holdings. This is a return to the name: Arrowpoint Investment Partners previously reported a position in IMVT as recently as Q4 2025.

Arrowpoint Investment Partners first reported a position in IMVT in Q4 2025 and has held it in 2 quarters since. The position peaked at $349K in Q4 2025. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Arrowpoint Investment Partners held 9,043 shares of Immunovant worth $348K as of Q2 2026.
  • Immunovant was a new Arrowpoint Investment Partners position in Q2 2026.
  • Immunovant made up 0.08% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #84 holding.
  • Arrowpoint Investment Partners first reported a position in Immunovant in Q4 2025 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Immunovant position peaked at $349K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.